Trial Profile

Phase I, Open Label, Multicenter, Dose Escalation and Expansion Study of IMJ995 in Acute Lymphoblastic Leukemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 23 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMJ 995 (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

20 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
27 Sep 2022 Planned End Date changed from 3 Jul 2026 to 13 Aug 2026.
27 Sep 2022 Planned primary completion date changed from 3 Jul 2026 to 13 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com